106 filings
6-K
ASLN
ASLAN Pharmaceuticals Ltd
14 Jun 24
Aslan Pharmaceuticals Announces Plan to Implement Ads Ratio Change
4:46pm
6-K
ASLN
ASLAN Pharmaceuticals Ltd
31 May 24
Current report (foreign)
4:25pm
6-K
ASLN
ASLAN Pharmaceuticals Ltd
9 May 24
Aslan Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:10am
6-K
ASLN
ASLAN Pharmaceuticals Ltd
7 May 24
Current report (foreign)
7:41am
6-K
ASLN
ASLAN Pharmaceuticals Ltd
22 Apr 24
Aslan Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab In Dupilumab-experienced Atopic Dermatitis Patients
8:29am
6-K
35rfcuw gdrihwjx53n
19 Apr 24
Aslan Pharmaceuticals Announces Receipt of Nasdaq Notice
5:01pm
6-K
wjhaaia0da5
12 Apr 24
Amendment No. 2 to the Open Market Sale Agreementsm
8:10am
6-K
y1s0k4
12 Apr 24
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
6:05am
6-K
qqu0ocpjj9phhoa
13 Mar 24
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
7:27am
6-K
fzc5vmdac zx
11 Mar 24
ASLAN PHARMACEUTICALS PROVIDES TREK-DX STUDY UPDATE AND HIGHLIGHTS potENTIAL of EBLASAKIMAB in DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS
8:03am
6-K
8wgourbszw61 38l
24 Jan 24
Current report (foreign)
7:52am
6-K
l592qj lsd
8 Jan 24
Aslan Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
7:02am
6-K
6pgztlio
22 Dec 23
Current report (foreign)
4:24pm
6-K
rrs1cgz iwkgoi0zn90
8 Dec 23
Current report (foreign)
4:42pm
6-K
fx7s4j
27 Oct 23
Aslan Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:14am
6-K
l84d t209r6r670
24 Oct 23
Aslan Pharmaceuticals to Co-host Kol Panel Discussion Today on Changes In the Clinical Trial and Treatment Landscape for Atopic Dermatitis
8:32am
6-K
u46z xrtp8
16 Oct 23
Current report (foreign)
6:08am
6-K/A
5l3h n1ja7pw2nn
18 Aug 23
Current report (foreign) (amended)
7:33am
6-K
ycsej2j
11 Aug 23
Aslan Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
387hb00 ecls0xb9
20 Jul 23
Current report (foreign)
7:55am